Sitagliptin Prophylaxis for Glucocorticoid-Induced Impairment of Glucose Metabolism and Beta-Cell Dysfunction in Males With the Metabolic Syndrome X: A Randomized, Placebo-Controlled, Double-Blind Intervention Study With a 2x2 Factorial Design.

Trial Profile

Sitagliptin Prophylaxis for Glucocorticoid-Induced Impairment of Glucose Metabolism and Beta-Cell Dysfunction in Males With the Metabolic Syndrome X: A Randomized, Placebo-Controlled, Double-Blind Intervention Study With a 2x2 Factorial Design.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2014

At a glance

  • Drugs Sitagliptin (Primary) ; Prednisolone
  • Indications Metabolic syndrome
  • Focus Therapeutic Use
  • Acronyms SPHINX
  • Most Recent Events

    • 29 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Jun 2012 Actual patient number is 82 according to ClinicalTrials.gov.
    • 29 Jun 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top